145 related articles for article (PubMed ID: 35977253)
1. Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas.
Heijnsdijk EAM; Gulati R; Lange JM; Tsodikov A; Roberts R; Etzioni R
JAMA Health Forum; 2022 May; 3(5):e221116. PubMed ID: 35977253
[TBL] [Abstract][Full Text] [Related]
2. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
3. The prostate cancer screening clinic in the Bahamas: a model for low- and middle-income countries.
Roberts R; Mitchell C; Tancawan AL; Pedican M; Jones GW
Cancer Causes Control; 2017 Nov; 28(11):1187-1193. PubMed ID: 29119339
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
5. Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.
Heijnsdijk EAM; Gulati R; Tsodikov A; Lange JM; Mariotto AB; Vickers AJ; Carlsson SV; Etzioni R
J Natl Cancer Inst; 2020 Oct; 112(10):1013-1020. PubMed ID: 32067047
[TBL] [Abstract][Full Text] [Related]
6. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas.
Jones GW; Kellini O; Roberts R; Girgis N; Brown C; Nottage K; McGowan T; Quee-Brown CS; Brown C
Cancer Causes Control; 2017 Nov; 28(11):1285-1293. PubMed ID: 28864839
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
9. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
10. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.
Vettenranta A; Murtola TJ; Raitanen J; Raittinen P; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
JAMA Oncol; 2022 Jan; 8(1):61-68. PubMed ID: 34817559
[TBL] [Abstract][Full Text] [Related]
12. Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era.
Sammon JD; Dalela D; Abdollah F; Choueiri TK; Han PK; Hansen M; Nguyen PL; Sood A; Menon M; Trinh QD
J Urol; 2016 Apr; 195(4 Pt 1):913-8. PubMed ID: 26598427
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
14. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study.
Palsdottir T; Nordstrom T; Karlsson A; Grönberg H; Clements M; Eklund M
BMJ Open; 2019 Mar; 9(3):e027958. PubMed ID: 30928965
[TBL] [Abstract][Full Text] [Related]
15. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
16. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
17. Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort.
Bergengren O; Westerberg M; Holmberg L; Stattin P; Bill-Axelson A; Garmo H
JAMA Netw Open; 2021 May; 4(5):e219444. PubMed ID: 33999165
[TBL] [Abstract][Full Text] [Related]
18. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
19. Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.
Gulati R; Morgan TM; A'mar T; Psutka SP; Tosoian JJ; Etzioni R
J Natl Cancer Inst; 2020 Apr; 112(4):384-390. PubMed ID: 31225597
[TBL] [Abstract][Full Text] [Related]
20. The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial.
Godtman RA; Kollberg KS; Pihl CG; Månsson M; Hugosson J
Eur Urol; 2022 Sep; 82(3):311-317. PubMed ID: 35120773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
